| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Pseudocoptisine chloride targets acetylcholinesterase (AChE). AChE is an enzyme that breaks down the neurotransmitter acetylcholine in the synaptic cleft. By inhibiting AChE with an IC50 of 12.8 μM, Pseudocoptisine chloride increases the concentration of acetylcholine, thereby enhancing cholinergic transmission. This mechanism is relevant to the treatment of neurodegenerative diseases like Alzheimer's disease. The compound also exhibits anti-inflammatory effects.
|
|---|---|
| ln Vitro |
In RAW264.7 cells, pseudocoposite (0, 60, 90 μM; 1 hour) dose-dependently suppresses NO generation produced by LPS [2]. Pseudocoptisine (30-90 μM; 1 hour; RAW264.7 cells) dramatically lowers the mRNA expression of TNF-α and IL-6 that are produced in response to LPS [1]. Pseudocoptisineacetate decreases pro-inflammatory mediators such iNOS, COX-2, TNF-α, and IL-6 by blocking ERK and p38 phosphorylation in RAW 264.7 cells, which in turn prevents NF-kappaB activation [1].
In vitro, Pseudocoptisine chloride inhibits acetylcholinesterase (AChE) activity with an IC50 of 12.8 μM. It reduces the levels of pro-inflammatory mediators, such as iNOS, COX-2, TNF-alpha, and IL-6, through the inhibition of NF-kappaB activation via the suppression of ERK and p38 phosphorylation. It also shows anti-amnestic effects. These in vitro activities support its use in studying neurodegenerative diseases and inflammation. |
| ln Vivo |
The anti-amnestic effect of coptisine against scopolamine (1.0 mg/kg, intraperitoneal injection)-induced learning and memory impairment in mice was investigated. Pseudocoptisine (2.0 mg/kg, po) significantly corrected cognitive impairment in mice using passive avoidance testing [1].
In vivo data for Pseudocoptisine chloride is not extensively reported in publicly available sources. As an AChE inhibitor with anti-inflammatory and anti-amnestic properties, the compound has potential applications in animal models of neurodegenerative diseases like Alzheimer's disease and in models of cognitive impairment. However, specific published in vivo efficacy studies are not detailed in the current literature. Pseudocoptisine chloride is primarily used as a research tool. |
| Enzyme Assay |
The in vitro AChE inhibition assay for Pseudocoptisine chloride uses AChE enzyme (often from rat brain or electric eel) and a chromogenic substrate such as acetylthiocholine. The enzyme hydrolyzes the substrate to produce a thiol, which reacts with Ellman's reagent (DTNB) to produce a yellow color. The compound is added at various concentrations, and the inhibition of AChE activity is measured spectrophotometrically. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Pseudocoptisine chloride are conducted in immune cells such as RAW 264.7 macrophages to study its anti-inflammatory effects. Cells are stimulated with LPS to induce inflammation and treated with varying concentrations of the compound. The levels of pro-inflammatory mediators (iNOS, COX-2, TNF-alpha, IL-6) are measured by ELISA or Western blotting. NF-kappaB activation and ERK/p38 phosphorylation are assessed by Western blotting.
|
| Animal Protocol |
In vivo studies for Pseudocoptisine chloride would typically involve animal models of neurodegenerative diseases or cognitive impairment. The compound would be administered via oral or intraperitoneal routes. Efficacy would be assessed by measuring cognitive function using behavioral tests (e.g., Morris water maze) and by evaluating neuroinflammatory markers in the brain. However, specific published in vivo protocols for Pseudocoptisine chloride are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Pseudocoptisine chloride is not extensively reported in publicly available sources. The compound has a molecular weight of 355.77 and a molecular formula of C19H14ClNO4. As a quaternary alkaloid, it may have limited oral bioavailability. Detailed PK parameters such as half-life and bioavailability are not available in the current literature.
|
| Toxicity/Toxicokinetics |
Toxicity data for Pseudocoptisine chloride is limited. As with all research compounds, Pseudocoptisine chloride is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment. Its natural product origin suggests a potential safety profile.
|
| References |
|
| Additional Infomation |
Pseudocoptisine chloride (Isocoptisine chloride; CAS 30044-78-1) is a quaternary alkaloid from Corydalis tuber that inhibits acetylcholinesterase (IC50 = 12.8 μM). It exhibits anti-inflammatory and anti-amnestic properties, making it a valuable research tool for studying neurodegenerative diseases, cognitive function, and inflammation. It is for research use only and is not intended for human therapeutic applications.
|
| Molecular Formula |
C19H14NO4
|
|---|---|
| Molecular Weight |
320.319
|
| Exact Mass |
355.061
|
| CAS # |
30044-78-1
|
| Related CAS # |
Pseudocoptisine acetate;30426-66-5
|
| PubChem CID |
85777785
|
| Appearance |
Yellow to brown solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
25
|
| Complexity |
502
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
c12c([H])c3c([H])c4OC([H])([H])Oc4c([H])c3c([H])[n+]1C(C(c1c-2c([H])c2OC([H])([H])Oc2c1[H])([H])[H])([H])[H]
|
| InChi Key |
QBOVLUUBUAZWIN-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C19H14NO4.ClH/c1-2-20-8-13-6-18-17(22-9-23-18)5-12(13)3-15(20)14-7-19-16(4-11(1)14)21-10-24-19;/h3-8H,1-2,9-10H2;1H/q+1;/p-1
|
| Chemical Name |
5,7,18,20-tetraoxa-13-azoniahexacyclo[11.11.0.02,10.04,8.015,23.017,21]tetracosa-1(24),2,4(8),9,13,15,17(21),22-octaene;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~1 mg/mL (~2.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1219 mL | 15.6094 mL | 31.2188 mL | |
| 5 mM | 0.6244 mL | 3.1219 mL | 6.2438 mL | |
| 10 mM | 0.3122 mL | 1.5609 mL | 3.1219 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
